Simin Zhang, Jianfeng Quan and Ye Tian
Affiliated Hospital of Shaanxi University of Chinese Medicine, Xianyang 712000, China
To investigate the significance of Her-2 transformation in breast cancer after treatment. A case of breast cancer with lung metastasis was reported. The second biopsy showed Her2 transformation, and anti Her2 treatment was performed and the literature was reviewed. Before treatment, the primary lesion of the patient was Luminal B type, Her2 was negative, and after comprehensive treatment, the needle biopsy of pulmonary metastatic lesions was Her2 positive. Her2 status of patients with breast cancer may change after comprehensive treatment, and re biopsy can be considered to provide more treatment opportunities for patients.
Breast Cancer, Secondary Biopsy, Her-2 Transition
Simin Zhang, Jianfeng Quan and Ye Tian. Her-2 Transformation in Lung Metastasis of Breast Cancer: A Case Report and Literature Review. International Journal of World Medicine(2023), Vol. 4, Issue 2: 20-27. https://doi.org/10.38007/IJWM.2023.040203.
 Liu, Z., Li, X.N. and Luo, Z.Q. (2017) Correlation between the positive rate of tumor markers and pathological classification of breast cancer. Laboratory medicine, 32(5): 446-448.
 Zhao, Y., Deng, X. (2015) Molecular typing and treatment of breast cancer. Chinese Journal of Practical Surgery, 35(7):704-708.
 Nakajima, H., Fujiwara, I., Mizuta, N., et al. (2008) Prognosis of Japanese breast cancer based on hormone receptor and HER2 expression determined by immunohistochemical staining. World J Surg, 32(11):2477-2482. https://doi.org/10.1007/s00268-008-9712-8
 Lang, Z., Wu, Y., Li, C., et al. (2017) Multifocal and multicentric breast carcinoma: a significantly more aggressive tumor than unifocalbreast cancer. Anticancer Research, 37(8):4593-4598. https://doi.org/10.21873/anticanres.11858
 Nauroth, A., Kalder, M., Rössler, M., et al. (2017) Conversion of hormone and HER-2 receptor in metachronous neck metastases from breast carcinoma. J Cancer Res Clin Oncol, 143: 1811-1814. https://doi.org/10.1007/s00432-017-2426-2
 MetastasisLôrincz, T., Tóth, J., Badalian, G. et al. (2006) HER-2/neu Genotype of Breast Cancer May Change in Bone. HER-2/neu genotype of breast cancer may change in bone metastasis. Pathol Oncol Res, 12: 149-52. https://doi.org/10.1007/BF02893361
 Wang, R.X. (2018) Studies on the heterogeneity of expression of commonly used molecular biological indicators of breast cancer 2018 Nanjing Medical University Doctoral dissertation.
 Shen, Z.L. (2014) Comparative analysis of ER, PR and HER-2/neu in breast cancer primary and axillary lymph node metastases. Wenzhou Medical University.
 Oldham, E.A., Li, C., Ke, S., et al. (2000) Comparison of action of paclitaxel and poly (Lglutamic acid)-paclitaxel conjugate in human breast cancer cells. Int Joncol. 16: 125–320. https://doi.org/10.3892/ijo.16.1.125
 Chen, H.R., Wu, Y.T., Yu, Q.B., Yang, Y.Y., Wei, Y.X., Li, H.Y., Wu, K.N. and Kong, L.Q. (2017) Negative genic switch of HER-2 in the primary tumor instead of the synchronous metastatic nodal lesions after neoadjuvant chemotherapy in a patient with primary HER2-positive breast cancer. World J Surg Oncol. Oct 19; 15(1):189. https://doi.org/10.1186/s12957-017-1255-8
 Li, P., Liu, T., Wang, Y., Shao, S., Zhang, W., Lv, Y., Yi, J. and Wang, Z. (2013) Influence of neoadjuvant chemotherapy on HER2/neu status in invasive breast cancer. Clin Breast Cancer. Feb; 13(1):53-60. https://doi.org/10.1016/j.clbc.2012.09.011
 De, L.A., Cruz, L.M., Harhay, M.O., Zhang, P. and Ugras, S. (2018) Impact of Neoadjuvant Chemotherapy on Breast Cancer Subtype: Does Subtype Change and, if so, How? : IHC Profile and Neoadjuvant Chemotherapy. Ann Surg Oncol. Nov; 25(12):3535-3540. https://doi.org/10.1245/s10434-018-6608-1
 Guarneri, V., Dieci, M.V., Barbieri, E., et al. (2013) Loss of HER2 positivity and prognosis after neoadjuvant therapy in HER2- positive breast cancer patients. Ann Oncol, 24(12):2990-2994. https://doi.org/10.1093/annonc/mdt364
 Niikura, N., Liu, J., Hayashi, N., et al. (2012) Loss of human epidermal growth factor receptor 2 (HER2) expressions in metastatic sites of HER2overexpressing primary breast tumors. J Clin Oncol, 30(6): 593-599. https://doi.org/10.1200/JCO.2010.33.8889
 Wang, R.X., Chen, S., Jin, X., et al. (2017) Weekly paclitaxel Plus carboplatin with or without trastuzumab as neoadjuwant chemotherapy for HER2-positive breast cancer: loss of HER2 amplification and its impact on response and prognosis.Breast Cancer Res Treat , 161(2):259-267. https://doi.org/10.1007/s10549-016-4064-9
 Liu, J.L., Chen, D.S., Hu, H., et al. (2022) Predictors of neoadjuvant therapy response for HER2-positive invasive breast cancer and assessment of HER2 status changes before and after treatment. Chinese Journal of Cancer.
 Zong, Y. and Pegram, M. (2021) Research advances and new challenges in overcoming triple - negative breast cancer. Cancer Drug Resist, 4(3):517. https://doi.org/10.20517/cdr.2021.04
 Li, L.L. (2015) Transformation of related receptors after breast cancer progression and its clinical significance. Hebei Medical University.
 Zhang, S. (2012) Changes of ER, PR, Her-2 and Ki67 in breast cancer before and after neoadjuvant chemotherapy. Zhejiang University.
 Jiang, N.Y. (2017) Heterogeneity of ER, PR and HER-2 expression between lesions in patients with advanced breast cancer. Zhejiang University.
 Wang, Y.Z., Si, W., Yang, J.L. (2015) Changes of Hormone Receptor and HER-2 Expression before and after Recurrence and Metastasis of breast cancer and Their Clinical Significance. PLA Medical College, (8):769-772.s
 Zheng, Y.H., Yang, Y.H. and Qiu, X.W. (2013) Comparison of IHC and FISH detection methods for HER2 gene in breast cancer and their relationship with clinic pathology. Journal of Fujian Medical University, (5):293-296.